Child with SARS-CoV-2 infection and acute lymphoblastic leukemia

Ralucă Bontea¹, Geta Vancea¹,², Dana Ispas¹, Nicoleta Tudor¹, Nicoleta Voicu¹, Cristina Iordache¹, Gabriela Scurtu¹, Andreea Stoenescu¹,², Andreea Popică¹, Claudia Chirilă¹, Simin-Aysel Florescu¹,², Emanoil Ceaușu¹,²,³, Petre Calistru¹,²

¹ “Dr. Victor Babes” Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania
² “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
³ Academy of Medical Sciences, Romania

ABSTRACT

Introduction. Coronavirus disease 2019 (COVID-19) frequently leads to asymptomatic or mild infectious disease evolution in children.

Case presentation. We present the case of a 3 year old girl, known with acute lymphoblastic leukemia in chemotherapy treatment at that time. She had an asymptomatic form of COVID-19 but with important paraclinical changes. The evolution was favorable under the treatment initiated with antibiotics, corticotherapy, gastric protector and symptomatic treatment if necessary.

Conclusion. Management of children with COVID-19 and other comorbidities remains a challenge given the few data currently in the literature.

Keywords: COVID-19, acute lymphoblastic leukemia, immunodepression, children

INTRODUCTION

First appearing in Wuhan, China, in December 2019, SARS-CoV-2 virus infection has spread rapidly to all continents. Children are less affected compared to adults. In children, the signs and symptoms of the disease are comparable to those of adults with a predominance of mild and even asymptomatic forms of the disease (1,2). Unlike other viral pathogens, it appears that SARS-CoV-2 infection does not present a higher risk of respiratory complications in immunosuppressed patients, destruction of lung tissue during infection also depends on the host’s immune response (3). Currently, there are few data on the impact of COVID-19 on the immunocompromised population. Most studies focus on adults, with very few studies on immunosuppressed children.

CASE PRESENTATION

We present the case of a child, female, aged 3 years and 4 months, hospitalized in our clinic in May 2020. The child comes from twin pregnancy and he is known with acute lymphoblastic leukemia type B in clinical and hematological remission (diagnosed in September 2018) undergoing treatment with Methotrexate, Purinetol, Sumetrolim and Liv52. The background treatment was stopped about a week before hospitalization at the indication of the hematologist who observed in the routine tests of the patient leukopenia with neutropenia. Given the epidemiological context at that time, the attending physician recommended to perform the SARS-CoV-2 RT-PCR. The test confirmed the infection with the new coronavirus, which is why she was admitted to our clinic for surveillance, investigations and specialized treatment.
Informed consent of the mother was obtained for clinical examination, blood tests and treatment of the child.

Clinical findings

The child did not show any clinical signs or symptoms during admission.

Diagnostic focus and assessment: Biological investigations at the time of presentation showed: leukopenia (3,000/µl), neutropenia (500/µl), lymphopenia (1,600/µl), slightly increased ALT (92 U/L), the rest of the analyses (inflammation markers, coagulation samples, IL-6, ferritin, creatinine, glucose, ionogram, urine summary, pharyngeal exudate) being within normal limits. Pulmonary radiography shows interstitial infiltrates with minimal associated alveolar component, diffusely distributed in the lower halves of both lung fields.

Therapeutic focus and assessment

Because the radiological image raises the high suspicion of bacterial infection in a host immunocompromised by the underlying disease and the chemotherapy treatment received, to which was added corticotherapy, it was decided to start the treatment, for curative and prophylactic purposes for possible severe bacterial infection, the patient received treatment with Cefort 1400 mg/day iv, because it could not be maintained venous approach, it was decided to replace it with Augmentin 400 mg/57 mg/5 ml, 12 ml/day, administered in two doses, for 7 days, Azithromycin 200 mg/5ml, 5 ml/day po, for 10 days, Dexamethasone 6mg/day iv, administered in two doses, for 7 days then 3 mg/day iv, administered in two doses, 2 more days, Omex 10 mg/day po and Liv52. On the eighth day of hospitalization, the SARS-CoV-2 RT-PCR test was repeated with a negative result. The clinical and paraclinical evaluations during SARS-CoV-2 virus infection until healing, to detect in advance a possible unfavorable course of the disease.

CONCLUSIONS

It is confirmed that in childhood SARS-CoV-2 infection often develops asymptptomatically. In our case, the asymptomatic evolution was present in a child with immunosuppression caused by a hematological underlying disease with undergoing chemotherapy with favorable evolution.

REFERENCES